FDA Oncology Division Invites Advocates To Play Early Role In Cancer Drug Review.
Thompson Names Texas Health Official Head Of HHS Center For Faith-Based Initiatives.
Foundation Gives Duke $2M For Brain Tumor Research.
Democrats Say Bush Budget Neglects NSF And NASA.
Seattle Times, The Hutch Duel Over Five-Part Series.
NCI Offers Bibliography On Risk Communication.
SEER Program Expansion Through Cost-Sharing.
Toxicology Program Seeks Comment On Substances.
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”









